Profile of Interleukin-6 and Tumor Necrosis Factor-α in Hospitalized COVID-19 Patients

Abstract

Abstract Background: In 2019’s December, the new COVID-19 coronavirus induced severe lower respiratory tract syndrome in Wuhan, China. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ultimately became responsible for the life-threatening pandemic. The magnitude and outcome of COVID-19 may be related to the overproduction of pro-inflammatory cytokine called “cytokine storm.” Cytokine production besides the age of patients, and comorbidities, all influence the length and severity of SARS-CoV-2. Objectives: This research was performed to investigate how these factors affect patients who have severe COVID-19 in a sample of Iraqi patients. Materials and Methods: A total of 82 participants were enrolled in this work, confirmed hospitalized COVID-19 patients (n = 60) and healthy control (n = 22) from both sexes of age range 20‐67 years. Tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) levels in the serum of COVID-19 patients and HC have been evaluated using an ELISA. Results: According to our findings, sera from COVID-19 patients had considerably higher levels of IL-6 and TNF-α than those of the control group. Furthermore, most infections were among women (63%), followed by men (37%), the higher number of patients were within 50‐59 years, while the lowest number of patients was found in the group 20‐29 years. Most COVID-19 patients appeared to be overweight and obese. Additionally, those who have diabetes mellitus are also at risk of severe COVID-19. Conclusion: Serum levels of TNF-α and IL-6 were higher in patients than in the control group, suggesting that they could be used as indicators of the severity of COVID-19 illness. Also, their combined detection provided highest specificity and sensitivity for early prediction of COVID-19 severity, which has significant clinical values.